Bharat Biotech’s Covid-19 vaccine Covaxin phase-3 trials crosses half-way mark at 13,000 volunteers

Bharat Biotech on Tuesday announced successful recruitment of 13,000 volunteers and continued progress towards achieving the goal of 26,000 participants for Phase-3 clinical trial of first Make in India vaccine candidate, Covaxin across multiple sites in India. This is India’s first and only Phase 3 efficacy study for a COVID-19 vaccine, and the largest phase III efficacy trial ever conducted for any vaccine in India.

from IndiaTV India: Google News Feed https://ift.tt/3riUdaK
via